Periconceptional Over-the-Counter Nonsteroidal Anti-inflammatory Drug Exposure and Risk for Spontaneous Abortion

University of North Carolina at Chapel Hill, North Carolina, United States
Obstetrics and Gynecology (Impact Factor: 5.18). 07/2012; 120(1):113-22. DOI: 10.1097/AOG.0b013e3182595671
Source: PubMed


To estimate the association between over-the-counter nonsteroidal anti-inflammatory drug (NSAID) exposure during the early first trimester and risk for spontaneous abortion (gestation before 20 weeks of gestation) in a prospective cohort.
Women were enrolled in the Right from the Start study (2004-2010). Exposure data regarding over-the-counter NSAID use from the last menstrual period (LMP) through the sixth week of pregnancy were obtained from intake and first-trimester interviews. Pregnancy outcomes were self-reported and verified by medical records. Gestational age was determined from the LMP. Stage of development before loss was determined from study ultrasonography. Cox proportional hazards regression models were used to estimate the association between NSAID exposure and pregnancy outcome taking into account candidate confounders.
Among 2,780 pregnancies, 367 women (13%) experienced a spontaneous abortion. NSAID exposure was reported by 1,185 (43%) women. NSAID exposure was not associated with spontaneous abortion risk in unadjusted models (hazard ratio [HR] 1.01, 95% confidence interval [CI] 0.82-1.24) or models adjusted for maternal age (adjusted HR 1.00, 95% CI 0.81-1.23).
Our findings suggest that use of nonprescription over-the-counter NSAIDs in early pregnancy does not put women at increased risk of spontaneous abortion.

0 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Nonsteroidal anti-inflammatory drugs(NSAIDs) are one of the most common medications reported in pregnancy. NSAIDs directly impact prostaglandin pathways, and have been proposed as potential risk factors for spontaneous abortions(SAB, gestation <20 weeks’). SAB risk and drug response across several medications differ by race; therefore, we evaluated whether associations between NSAIDs and SAB risk differ by race. Methods Women were enrolled the Right from the Start(2004-2010) prospective cohort. Data regarding over-the-counter(OTC) NSAIDs up to the sixth week of pregnancy were obtained from interviews. Race was self-reported. Cox proportional hazards regression models were used to estimate the association between NSAID exposure and SAB, adjusted for confounders. Results Among 2,493 pregnancies, 12% were African American(AA) and 88% were Caucasian(CA). NSAID exposure was reported by 40%(n=124) of AAs, and 43%(n=945) of CAs. Race stratified analyses showed protection from SAB among AAs(adjusted hazard ratio [aHR]=0.84, 95% CI 0.73, 0.96), but no effect in CAs(aHR=1.01, 95% CI 0.88, 1.16). Conclusions Our findings suggest that risk for SAB due to OTC NSAIDs in early pregnancy is modified by race. Further investigation of dose, timing in gestation and indication may help to further reconcile the relationship between race, NSAIDs, and SAB.
    No preview · Article · Jan 2013 · Annals of epidemiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Decisions regarding medication use during pregnancy are amongst the most challenging clinicians will face. The health of both the mother and the developing fetus must be taken into account when designing a treatment plan. Limited data on an individual drug's risk for use during pregnancy and conflicting recommendations regarding drug safety contribute to uncertainty in therapy choices. Clinicians and patients individually have their own risk tolerance for prescribing and taking medications. Finally, pregnancy itself can impact an individual patient's disease activity rendering typical treatment approaches invalid. This chapter will discuss the treatment of the pregnant and nursing woman with a rheumatic disease. It will review the literature on commonly used medications for rheumatic disease management including aspirin, the nonsteroidal anti-inflammatory medications and COX-2 inhibitors; the glucocorticoids; the antimalarials; sulfasalazine; the immunosuppressive agents azathioprine and 6-mercaptopurine, cyclosporine, mycophenolate mofetil, and tacrolimus; the anti-metabolite methotrexate; leflunomide; cylophosphamide; intravenous immunoglobulin; the biologics including tumor necrosis factor-α (TNF-α) blockers, rituximab, belimumab, actemra, anakinra, abatacept, and tocilizumab; the anti-coagulants warfarin and unfractionated and fractionated heparin and colchicine. Wherever possible, specific recommendations will be made. © 2014 Springer Science+Business Media New York. All rights are reserved.
    No preview · Chapter · Mar 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the recent literature on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and traditional disease-modifying antirheumatic drugs before and during pregnancy. Recent data suggest that the risk of cleft palate formation after in-utero glucocorticoid exposure is lower than previously reported. Two studies of inadvertent leflunomide exposure during early pregnancy suggest that this medication may be less teratogenic than previously thought. Although NSAIDs are well tolerated for use during the first two trimesters of pregnancy, they should be avoided during a conception cycle so as not to impede implantation. After gestational week 30, these medications should be discontinued as they may cause premature closure of the ductus arteriosus. The nonfluorinated glucocorticoids, prednisone and prednisolone, can be used throughout pregnancy, although use during the first trimester may increase the risk of cleft palate formation. Protracted glucocorticoids exposure during pregnancy can cause maternal preterm premature rupture of the membranes, gestational hypertension and gestational diabetes. Methotrexate and leflunomide are teratogenic and should be avoided during pregnancy. The immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with pregnancy.
    No preview · Article · Mar 2014 · Current opinion in rheumatology
Show more